{"analyses":[{"ciLowerLimit":"0.477","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.030","groupDescription":"Cough for TC3 or IC3-WT Populations","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified analysis","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.984"},{"ciLowerLimit":"0.569","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.604","groupDescription":"Dyspnea for TC3 or IC3-WT Populations","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified analysis","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.955"},{"ciLowerLimit":"0.472","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.222","groupDescription":"Chest pain for TC3 or IC3-WT Populations","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified analysis","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.024"}],"classes":[{"categories":[{"measurements":[{"comment":"Median TTD is not estimable by Kaplan-Meier method due to insufficient observed events.\n\nLower/Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median TTD is not estimable by Kaplan-Meier method due to insufficient number of observed events.\n\nUpper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events.","groupId":"OG001","lowerLimit":"21.5","upperLimit":"NA","value":"NA"}]}],"title":"Cough"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"19.5","value":"11.8"},{"comment":"Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events.","groupId":"OG001","lowerLimit":"7.0","upperLimit":"NA","value":"11.1"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"comment":"Median TTD is not estimable by Kaplan-Meier method due to insufficient number of observed events.\n\nLower/Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median TTD is not estimable by Kaplan-Meier method due to insufficient number of observed events.\n\nLower/Upper limit of 95% confidence interval is not estimable by Brookmeyer and Crowley method due to insufficient number of observed events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Chest pain"}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"TTD in patient-reported lung cancer symptoms, defined as time from randomization to deterioration (10-point change) in any of the following symptom subscales (cough, dyspnea \\[multi-item scale\\], and chest pain), whichever occurs first, as measured by the EORTC QLQ-LC13. EORTC QLQ-LC13 module incorporates one multi-item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"},{"description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG001","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"Analysis was performed for the TC3 or IC3-WT Populations.","reportingStatus":"POSTED","timeFrame":"Baseline until data cut-off on 10 September 2018 (up to approximately 38 months)","title":"TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations","type":"SECONDARY","unitOfMeasure":"Months"}